R
ANDOMIZED CONTROLLED trials (RCTs) provide the basis for physicians to practice evidence-based medicine and have revolutionized the treatment of cardiovascular disorders. Due to their strict inclusion and exclusion criteria, RCTs do not always provide an accurate view of the burden of disease or long-term prognosis. In contradistinction, registries enable a real-world estimation of actual disease treatments. In the setting of acute coronary syndromes, several registries have provided insight into real-world event rates, treatment patterns, and outcomes. [1] [2] [3] [4] The clinical knowledge base regarding acute coronary syndromes is welldefined, but no comparable international data set is available to describe the risk profiles and treatment of individuals with stable atherothrombotic disease as defined in primary care practices. Although several advances based on RCTs have been made in the management of atherothrombosis, 5-9 the number of registries or population-based studies have been limited. The Framingham study, for example, continues to provide useful data on risk factors for developing atherothrombosis, but it is restricted to a particular geographic locale and does not fully address subsequent risk of patients with established vascular disease. 10, 11 The Reduction of Atherothrombosis for Continued Health (REACH) Registry was initiated to evaluate outpatients who would represent the entire spectrum of stable atherosclerotic clinical syndromes: from those with risk factors (but who are asymptomatic) to those with established atherosclerotic arterial disease within any circulatory bed. The REACH Registry was designed to provide these data from the most geographically and ethnically diverse population yet surveyed.
12 This article presents the baseline characteristics of the REACH Registry population.
METHODS
The REACH Registry is an international, prospective, observational registry designed to provide up to 24 months of clinical follow-up. The design of the REACH Registry has been published elsewhere.
12 Briefly, consecutive eligible outpatients aged 45 years or older with established coronary artery disease (CAD), cerebrovascular disease (CVD), or peripheral arterial disease (PAD), or with at least 3 atherosclerosis risk factors were enrolled over an initial 7-month recruitment period on a worldwide basis between December 2003 and June 2004; because of regulatory requirements in Japan, the enrollment in that country was delayed and occurred between August 2004 and December 2004 . For this reason, and also because of a desire on the part of the Japanese REACH investigators to analyze their data separately, the data from Japan were not analyzed together with the data from the rest of Asia. Medical record documentation was required for establishment of the presence of CAD, CVD, or PAD.
Documented CAD consisted of 1 or more of the following criteria: stable angina with documented CAD, history of unstable angina with documented CAD, history of percutaneous coronary intervention, history of coronary artery bypass graft surgery, or previous myocardial infarction. Documented CVD consisted of a hospital or neurologist report with the diagnosis of transient ischemic attack or ischemic stroke. Documented PAD consisted of 1 or both criteria: current intermittent claudication with anklebrachial index of less than 0.9 or a history of intermittent claudication together with a previous and related intervention, such as angioplasty, stenting, atherectomy, peripheral arterial bypass graft, or other vascular intervention including amputation.
The risk factors consisted of those that were documented in the medical record or for which patients were receiving treatment at the time of study enrollment: treated diabetes mellitus, diabetic nephropathy, ankle-brachial index of less than 0.9, asymptomatic carotid stenosis of 70% or higher, carotid intima media thickness of 2 times or more adjacent sites, systolic blood pressure of 150 mm Hg or higher despite therapy for at least 3 months, hypercholesterolemia treated with medication, current smoking of at least 15 cigarettes per day, men aged 65 years or older, or women aged 70 years or older. Patients already in a clinical trial, hospitalized patients, or those who might have difficulty returning for a follow-up visit were excluded from enrollment. This protocol was submitted to the institutional review board in each country according to local requirements and signed informed consent was obtained for all patients.
Selection of physicians to the REACH Registry was determined at the country level. To ensure homogeneity and a good representation in the REACH Registry population, a site selection method was designed and implemented in each participating country by epidemiologists under the supervision of the REACH Registry global and local steering committees and national coordinators. The site selection method took into account various and complex criteria such as patient profiles (eg, CAD, CVD, or PAD, or risk of atherothrombotic events), physician profiles (eg, general practitioners, internists, cardiologists, neurologists), health care environments (rural, suburban, urban) , and medical practices (office-based, hospital-based). This selection was designed to try to mimic the best available epidemiological data in each country that reflect the burden of atherothrombosis or at-risk populations. The national coordinator in each country made the final decision on the selection of physicians and sites in each country.
Data were collected centrally via use of a standardized international case report form, completed at the study visit. Baseline height, weight, waist circumference, seated systolic and diastolic blood pressure, and available fasting glucose and cholesterol levels were obtained. From these data, baseline demographic and risk factor characteristics were analyzed. Body mass index (BMI) was defined as weight in kilograms divided by the square of height in meters. Participants were considered to be overweight if they had a BMI of 25 to less than 30 or obese if they had a BMI of 30 or higher. Obese participants were further subclassified as having class I (BMI, 30-Ͻ35), class II (BMI, 35-Ͻ40), or class III obesity (BMI Ն40). Waist circumference was also used to classify patients as obese if it was 40 inches or larger (Ն102 cm) in men or 35 inches or larger (Ն88 cm) in women. Current smoking was defined as at least 5 cigarettes per day on average within the last month before entry into the REACH Registry; former smoking was defined as at least 5 cigarettes per day on average more than 1 month before entry into the REACH Registry. Polyvascular disease was defined as coexistent symptomatic (clinically recognized) arterial disease in 2 or 3 territories (coronary, cerebral, and/or peripheral) within each patient.
Family practitioners and general practitioners (44% of the physicians) as well as other office-based specialists in areas such as internal medicine (29%), cardiology (13%), neurology (9%), endocrinology (2%), general surgery (2%), vascular disease (1%), and other fields (1%) recruited patients into the study. Each physician recruited a maximum of 15 patients (maximum of 20 in the United States).
In each country, 10% of all sites that enrolled at least 1 patient underwent a data audit by completing a site visit. These sites were selected randomly 6% of the time and an additional 4% were selected due to the number of queries and missing data from the site. For each of the sites (10%) undergoing monitoring, 100% of case report forms for patients enrolled at that site were monitored for source documentation and accuracy.
The sample size for the REACH Registry was estimated as follows. It was assumed that a minimum of 40 000 individuals would be followed up for an average of 21 months (with Յ30% lost to follow-up) with a primary yearly event rate of 3% for cardiovascular death, myocardial infarction, or stroke. With these assumptions, the precision of the estimate would be 5% (range, 2.84%-3.16%).
Continuous variables are expressed as mean (SD) The population sample included 36.3% women and the mean (SD) age was 68.5 (10.1) years (interquartile range, 61-76 years). A high proportion of patients had diabetes, hypertension, and hypercholesterolemia. There were significant differences in the prevalence of risk factors such as diabetes (in Table 1 44.3% of the total population enrolled and in 37.5% of symptomatic patients) among the different patient subgroups. There was also marked geographic variation in the prevalence of diabetes, ranging from 52.5% in the Middle East to 27.7% in Eastern Europe. Current smoking prevalence was 15.3% overall, although in regions such as Eastern Europe, current smoking was present in 20.9% (FIGURE 1). Documented high blood pressure (systolic Ն140 mm Hg and/or diastolic Ն90 mm Hg), fasting hyperglycemia (glucose Ն126 mg/dL [Ն6.99 mmol/L]), and impaired fasting glu-
were recorded on the baseline visit in a substantial number of patients. Overall, 50% of patients had elevated blood pressure at baseline. Of patients with diagnosed hypertension, baseline blood pressure was elevated in 54.9%; of patients without diagnosed hypertension, baseline blood pressure was elevated in 27.6% (PϽ.001). Of patients without diagnosed diabetes, fasting hyperglycemia was present in 4.9% and impaired fasting glucose was present in 36.5%. In all geographic regions, a substantial percentage of patients had elevated levels of cholesterol (Ͼ200 mg/dL [5.18 mmol/L]), ranging from 24.4% in Australia to 64.4% in Eastern Europe. Of the patients with symptomatic atherothrombosis, a significant proportion (15.9%) had symptomatic polyvascular disease (FIGURE 2).
There was a high prevalence of overweight status and obesity (Table 1 and  Table 2 ). Overweight and obesity were prevalent throughout the world, but were higher in North America than in other regions (overweight: 37.1%; obese: 36.5%; morbidly obese: 5.8%; PϽ.001 vs other regions). Morbid obesity was (TABLE 4) . Of the total population, 78.6% were receiving some form of antiplatelet therapy and 69.4% were receiving statins. Medication use varied based on geography; for example, statin use was lowest in Japan. However, across geographic regions, the proportion of patients meeting established cholesterol targets was suboptimal. There was also substantial variation in patients' medication use by physician specialty (TABLE 5) . For example, cardiologists prescribed acetylsalicylic acid and statins significantly more often than other physician specialties.
COMMENT
Evidence-based medicine holds the promise to improve patient care globally. Based on RCTs, practice care guidelines have been developed and are being implemented throughout the world. 13 The REACH Registry demonstrates a substantial gap between recommendations in guidelines and actual clinical practice in the care of patients with or at risk for atherothrombosis. A pattern of underutilization of established medical therapies and lifestyle interventions is seen in the REACH Registry throughout all geographic regions studied, among different physician specialties, and across disease subtypes. Despite an overwhelming amount of data in support of statins and antiplatelet therapy, these classes of medicines are not being prescribed at optimal rates. A substantial proportion of patients receiving statins are not meeting established targets that are recommended in guidelines for cholesterol reduction, 14, 15 and newer data suggest even more aggressive targets. 16, 17 Only a minority of patients were at target goals for blood pressure, glucose, cholesterol, body weight, and nonuse of tobacco.
Risk factors present in patients with CAD, CVD, or PAD were observed to be remarkably consistent across vascular beds and across geographic regions in the REACH Registry. This latter observation is consistent with global observations in survivors of myocar- dial infarction in the INTERHEART study. 18 Overall, these findings highlight the importance of treating the core set of risk factors (hypertension, diabetes, hypercholesterolemia, tobacco use, and obesity) that appear to contribute to the bulk of the risk for developing atherothrombosis.
18 Treating such factors more aggressively to reach established goals would decrease the need for subsequent revascularization procedures. To date, no trial has demonstrated that revascularization is superior to medical therapy in reducing mortality in patients with stable CAD.
19 Therefore, it becomes even more important to find ways to improve the treatment of risk factors, such as by implementing care pathways and measuring adherence to guidelines. 1, 20, 21 Obesity has been identified as a major public health concern and the REACH Registry baseline data confirm the prevalence of obesity throughout the world. The rates in North America are particularly alarming and should serve as a signal to the rest of the world, especially to areas where urbanization and industrialization are occurring, which may expose populations that are particularly genetically susceptible to atherothrombosis and further accelerate the impact of atherothrombosis on morbidity and mortality. [22] [23] [24] Another interesting observation about obesity in the REACH Registry has to do with the definitions used. As defined by BMI, 30% of patients in this study population would be defined as obese. Alternatively, when obesity was defined by waist circumference, almost half of the patients were categorized as obese. Because more than 62 000 patients had a baseline waist circumference measurement, the follow-up phase of the REACH Registry should enable a comparison of these 2 metrics of obesity.
25-28 Furthermore, the thresholds at which obesity is linked 
29-32
In patients with established atherothrombosis, symptomatic polyvascular disease was common in the REACH Registry. One of 6 patients with CAD, CVD, or PAD had symptomatic involvement of 1 or 2 other arterial beds. This finding points to the diffuse nature of atherothrombosis and implies that atherothrombosis is best treated as a systemic disease. 33 Of course, if the degree of asymptomatic polyvascular disease was examined, the degree of overlap in the involvement of different arterial circulations would be even greater than seen in the present analysis.
There are several limitations to this analysis. While the REACH Registry is more geographically diverse than other registries that have examined populations with stable cardiovascular disease, this study does not include important geographic regions and ethnic groups (ie, the underrepresentation of African and Chinese populations, among many). By focusing on stable outpatients, the enrolled patients may be at a lower risk than if inpatients with atherothrombotic diseases had also been included. As for all registries, the influence of recruitment biases (which may vary geographically) cannot be known. Physicians were instructed to recruit consecutive patients, but unlike in an RCT, there were no log books audited to ensure compliance with such instructions. Despite efforts to ensure the inclusion of representative patients from every participating country, this study has limitations inherent to nonpopulation-based registries. We were not able to determine if undocumented contraindications to medications or economic limitations affected the lack of medication use. However, the magnitude of underrecognition and undertreatment of atherothrombosis risk factors is such that this finding is likely to be robust. Furthermore, physicians deciding to participate in a research initiative such as the REACH Registry may have been more apt to provide better care and therefore the findings of undertreatment may reflect a best-case scenario and actually underestimate the true degree of undertreatment in general clinical practice.
In conclusion, data from this large, international, contemporary registry demonstrate that patients with manifest atherothrombosis or those at risk are characterized by the common atherosclerosis risk factors, albeit with some significant international variability. These data demonstrate a strikingly elevated degree of obesity internationally as a critical cardiovascular risk factor. Despite a high prevalence of many risk factors, systematic undertreatment is evident throughout the regions studied. The prevalence of polyvascular disease in the patients with symptomatic atherothrombosis substantiates the cross-risk that patients face in arterial beds other than in their initial presenting one.
The percentages of overweight and obese patients support efforts at targeting this risk factor in patients along the atherothrombotic continuum of risk. The follow-up phase of the REACH Registry will allow measurement of the cardiovascular ischemic event rates of this population as well as an assessment of how these various risk factors affect the rate of subsequent morbidity and mortality and cardiovascular outcomes in a geographically diverse population. People who develop the habit of thinking of themselves as world citizens are fulfilling the first requirement of sanity in our time. . . . More and more, the choice for the world's people is between becoming world warriors or world citizens. -Norman Cousins (1915 -1990 INTERNATIONAL PREVALENCE AND TREATMENT OF CARDIOVASCULAR RISK FACTORS ©2006 American Medical Association. All rights reserved. 
